In terms of non-invasive diagnosis, CXCL8 has been incorporated in a combined index termed “NAFLD discriminant score”, together with adiponectin, TNF-α, and visfatin, to distinguish NASH from hepatic steatosis with a sensitivity and specificity of 90% and 66%, respectively [149]. This evidence concerns the gene CXCL8 and metabolic dysfunction-associated steatotic liver disease.